Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069891915> ?p ?o ?g. }
- W2069891915 endingPage "346" @default.
- W2069891915 startingPage "335" @default.
- W2069891915 abstract "Mantle cell lymphoma (MCL) is a malignancy of mature B cells characterized by aberrant expression of cyclin D1 due to the translocation t(11;14). Epigenomic and genomic lesions in pathways regulating B-cell activation, cell cycle progression, protein homeostasis, DNA damage response, cell proliferation and apoptosis contribute to its pathogenesis. While patients typically respond to first-line chemotherapy, relapse is the rule resulting in a median survival of 5–7 years. The PI3K/AKT/mTOR appears as a key pathway in the pathogenesis and can be targeted with small molecules. Most experience is with mTOR inhibitors of the rapamycin class. Second-generation mTOR inhibitors and the PI3K inhibitor CAL-101 are novel options to more effectively target this pathway. Bruton's tyrosine kinase inhibition by PCI-32765 has promising activity and indicates immunoreceptor signaling as a novel therapeutic target. Up to 50% of relapsed patients respond to the proteasome inhibitor bortezomib suggesting that MCL may be particularly sensitive to disruption of protein homeostasis and/or induction of oxidative stress. Recent work has focused on elucidating the mechanism of bortezomib-induced cytotoxicity and the development of second-generation proteasome inhibitors. DNA hypomethylating agents and histone deacetylase inhibitors effect epigenetic de-repression of aberrantly silenced genes. These epigenetic pharmaceuticals and HSP90 inhibitors can synergize with proteasome inhibitors. Finally, BH3 mimetics are emerging as tools to sensitize tumor cells to chemotherapy. Participation in clinical trials offers patients a chance to benefit from these advances and is essential to maintain the momentum of progress. Innovative trial designs may be needed to expedite the clinical development of these targeted agents." @default.
- W2069891915 created "2016-06-24" @default.
- W2069891915 creator A5030177657 @default.
- W2069891915 creator A5030524385 @default.
- W2069891915 creator A5030726651 @default.
- W2069891915 date "2011-11-01" @default.
- W2069891915 modified "2023-10-17" @default.
- W2069891915 title "New molecular targets in mantle cell lymphoma" @default.
- W2069891915 cites W1580240122 @default.
- W2069891915 cites W1965008416 @default.
- W2069891915 cites W1967018540 @default.
- W2069891915 cites W1970599858 @default.
- W2069891915 cites W1970815499 @default.
- W2069891915 cites W1974788142 @default.
- W2069891915 cites W1975301877 @default.
- W2069891915 cites W1975305152 @default.
- W2069891915 cites W1975913714 @default.
- W2069891915 cites W1976402300 @default.
- W2069891915 cites W1977070131 @default.
- W2069891915 cites W1977258127 @default.
- W2069891915 cites W1981711832 @default.
- W2069891915 cites W1981896461 @default.
- W2069891915 cites W1981950613 @default.
- W2069891915 cites W1986020395 @default.
- W2069891915 cites W1986036865 @default.
- W2069891915 cites W1987583882 @default.
- W2069891915 cites W1988703453 @default.
- W2069891915 cites W1993730501 @default.
- W2069891915 cites W1995197723 @default.
- W2069891915 cites W1996541484 @default.
- W2069891915 cites W1996931025 @default.
- W2069891915 cites W1999353132 @default.
- W2069891915 cites W2005458309 @default.
- W2069891915 cites W2005494948 @default.
- W2069891915 cites W2007886976 @default.
- W2069891915 cites W2009937603 @default.
- W2069891915 cites W2011360946 @default.
- W2069891915 cites W2013510617 @default.
- W2069891915 cites W2014852291 @default.
- W2069891915 cites W2015677689 @default.
- W2069891915 cites W2017333581 @default.
- W2069891915 cites W2020619763 @default.
- W2069891915 cites W2022446231 @default.
- W2069891915 cites W2023351948 @default.
- W2069891915 cites W2024277839 @default.
- W2069891915 cites W2024676945 @default.
- W2069891915 cites W2026642838 @default.
- W2069891915 cites W2027971058 @default.
- W2069891915 cites W2031100736 @default.
- W2069891915 cites W2031284766 @default.
- W2069891915 cites W2033944464 @default.
- W2069891915 cites W2038260677 @default.
- W2069891915 cites W2038683465 @default.
- W2069891915 cites W2039856481 @default.
- W2069891915 cites W2043253380 @default.
- W2069891915 cites W2049512057 @default.
- W2069891915 cites W2051449283 @default.
- W2069891915 cites W2051503798 @default.
- W2069891915 cites W2053839012 @default.
- W2069891915 cites W2054777324 @default.
- W2069891915 cites W2057710602 @default.
- W2069891915 cites W2060902443 @default.
- W2069891915 cites W2063533508 @default.
- W2069891915 cites W2063779563 @default.
- W2069891915 cites W2065751798 @default.
- W2069891915 cites W2074918415 @default.
- W2069891915 cites W2077494567 @default.
- W2069891915 cites W2079351745 @default.
- W2069891915 cites W2080278485 @default.
- W2069891915 cites W2080939719 @default.
- W2069891915 cites W2085006244 @default.
- W2069891915 cites W2086765333 @default.
- W2069891915 cites W2096330673 @default.
- W2069891915 cites W2097856894 @default.
- W2069891915 cites W2105172500 @default.
- W2069891915 cites W2106259441 @default.
- W2069891915 cites W2106833395 @default.
- W2069891915 cites W2106904404 @default.
- W2069891915 cites W2108483542 @default.
- W2069891915 cites W2109371953 @default.
- W2069891915 cites W2109553227 @default.
- W2069891915 cites W2110105488 @default.
- W2069891915 cites W2111530307 @default.
- W2069891915 cites W2115655607 @default.
- W2069891915 cites W2116393881 @default.
- W2069891915 cites W2120380960 @default.
- W2069891915 cites W2124221273 @default.
- W2069891915 cites W2130883918 @default.
- W2069891915 cites W2133934152 @default.
- W2069891915 cites W2134024590 @default.
- W2069891915 cites W2139582914 @default.
- W2069891915 cites W2144894645 @default.
- W2069891915 cites W2150680216 @default.
- W2069891915 cites W2152694994 @default.
- W2069891915 cites W2153985422 @default.
- W2069891915 cites W2154423235 @default.
- W2069891915 cites W2154691188 @default.
- W2069891915 cites W2156813481 @default.